Follow NovoCure to never miss an important update.
Japan's Ministry of Health, Labour and Welfare approved the Optune Pax wearable device for use alongside chemotherapy in adults with advanced pancreatic cancer. This marks a significant expansion for the company's technology in one of the world's largest healthcare markets.
This is a key step in Novocure's plan to move beyond its original focus on brain cancer. Pancreatic cancer is notoriously difficult to treat, and adding a new geographic region for this specific use helps the company grow its total number of active patients, which is the most important metric for its long-term success.
Source: Business Wire
Timothy Scannell has retired from the board of directors, vacating his seat effective September 2, 2026. The company noted that his departure after five years of service was not due to any disagreement with management. While a board change at a medical technology firm is worth noting, this appears to be a routine and orderly retirement. It does not change the company's focus on expanding its cancer-treating wearable technology into new markets like lung and pancreatic cancer.
Source: 8-K filing
Novocure revealed that a cyberattack in mid-August exposed the records of more than 1,400 patients in the U.S. The company said the breach involved unauthorized access to its internal information systems.
While the number of affected patients is relatively small compared to the company's total user base, security incidents in healthcare are sensitive because they involve private medical data. This is worth watching to see if it leads to any regulatory fines or if the company has to spend more than expected to upgrade its digital security.
Source: Reuters
Novocure brought in about 184 million dollars in revenue last quarter, beating the 170 million dollars analysts expected. This growth was fueled by an 18 percent increase in the number of active patients using its Tumor Treating Fields therapy, which uses electric fields to treat aggressive cancers. The company also lost less money than expected, reporting a loss of 13 cents per share versus the 33 cents analysts predicted.
A key part of the growth story is the expansion into new types of cancer. The company recently received approval in Europe to treat pancreatic cancer with its Optune Pax device and already has more than 280 patients using it. For long-term owners, this quarter shows the business is successfully moving beyond its original focus on brain cancer and toward its goal of becoming a broader oncology platform.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The firm raised its target from 46 dollars to 52 dollars while keeping a buy rating on the stock. This move reflects confidence in the company's ability to grow its patient base and expand its therapy into new markets like pancreatic cancer. Even with the stock trading near 16 dollars, this target suggests the firm sees significant room for the price to rise as the business reaches more patients.
Source: H.C. Wainwright
Management has a history of setting conservative targets and clearing them, often reporting smaller losses than analysts expect while maintaining steady double-digit sales growth.
| Expectation | |
|---|---|
| EPS | $-0.24 |
| Revenue | $182M |